Extraordinary meeting of the Committee for Medicinal Products for Human Use (CHMP): 25 October 2021
EventHumanCOVID-19Vaccines
On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.
Date
Location
This extraordinary plenary meeting is organised in the context of the evaluation of an application for the use of a booster dose for the COVID-19 vaccine Spikevax.
The aim of the meeting is to conclude this evaluation, if possible.
The Committee for Medicinal Products for Human Use (CHMP) is responsible for preparing the Agency's opinions on all questions concerning human medicines.